Metizolam
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Metizolam (desmethyletizolam) is a synthetic depressant of the thienotriazolodiazepine class. It is the N-desmethyl structural analog of etizolam, distinguished by lower potency and reduced euphoria.[1] Metizolam is a positive allosteric modulator of the GABA-A, producing its effects by enhancing the brain's primary inhibitory signaling system.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, thienodiazepines, zolpidem +2 morebenzodiazepines, thienodiazepines, zolpidem, zopiclone, zaleplon show less
Disclosed in a 1975 Japanese patent covering the thienotriazolodiazepine class,[2] metizolam was never developed as a pharmaceutical and carries no clinical history.[3][4] The compound appeared on European research chemical markets in September 2015 as a designer benzodiazepine. It remains unscheduled internationally, though several European nations and Canada have placed it under national control.
Subjective effects include sedation, anxiety suppression, muscle relaxation, amnesia, and cognitive suppression. The experience is one of broad dampening — a quiet reduction of tension and mental sharpness without the pronounced euphoria of more potent designer benzodiazepines. Disinhibition, emotional suppression, and compulsive redosing are characteristic unsought effects.
Metizolam carries the benzodiazepine class risk of physical dependence with repeated use, though its toxicity when used alone is presumed low.[5] The primary lethal risk is respiratory depression when combined with opioids, alcohol, or other CNS depressants — a danger compounded by the fact that standard hospital drug screens may not detect it.[3] No clinical trials have been conducted; the current understanding rests on a single self-administration study in one volunteer and class-level inference from the broader benzodiazepine literature.[6]
History[edit]
Discovery
The thienotriazolodiazepine class was first described in a 1975 patent filed by researchers at Welfide Corporation in Japan.[2] Metizolam — the N-desmethyl structural analog of etizolam — was among the compounds covered by this patent family but was never selected for pharmaceutical development.[3][4] While etizolam proceeded to market as an anxiolytic in Japan, Italy, and India, metizolam remained a patent-stage curiosity for four decades.
Emergence as a designer drug
Metizolam appeared on European research chemical markets in September 2015, first identified as a light blue tablet by the University of Freiburg's Institute of Forensic Medicine.citation needed Danish customs independently identified the compound in a UK-origin shipment the following month.citation needed The Swedish STRIDA project reported four confirmed intoxication cases between 2012 and 2016,[7] and the first controlled human data came from a single self-administration study by Kintz et al..[6]
Present status
By 2020, twenty-nine designer benzodiazepines had been notified to the European Monitoring Centre for Drugs and Drug Addiction.[8] Metizolam remains among the least potent and least prominent of these, ranked alongside deschloroetizolam, nifoxipam, and pyrazolam in comparative user assessments.[1] No clinical trials have been registered for the compound in any jurisdiction.
The name metizolam follows benzodiazepine nomenclature convention, where the suffix "-zolam" denotes a triazolobenzodiazepine or thienotriazolodiazepine. The "meti-" prefix distinguishes it from its parent compound Etizolam, referencing the desmethyl modification. In research chemical communities, metizolam attracted limited interest relative to more potent analogs and has not acquired street names or cultural identity independent of the designer benzodiazepine category.
Chemistry[edit]
Structural class
Metizolam belongs to the thienotriazolodiazepine class — a tricyclic system in which a thiophene ring replaces the benzene ring of classical benzodiazepines, fused to a 1,4-diazepine and a 1,2,4-triazole.[3] This scaffold is shared with etizolam, from which metizolam differs only by the absence of a single methyl group on the diazepine nitrogen.
The triazole ring fusion is associated with higher predicted GABA-A binding affinity compared to non-triazolo benzodiazepines in structure-activity modeling.[4] A 2-chlorophenyl group occupies the pendant aryl position, and an ethyl group sits on the triazole ring.[9]
Molecular properties
| Molecular formula | C₁₆H₁₃ClN₄S |
| Molecular weight | 328.82 g/mol |
Stereochemistry
Metizolam contains no chirality centers and exists as a single stereochemical entity.
Pharmacology[edit]
Mechanism of action
Metizolam functions as a positive allosteric modulator of the GABA-A receptor.[5][4] Rather than activating the receptor directly, it binds to the benzodiazepine site on the GABA-A complex and amplifies the effect of GABA — the brain's primary inhibitory neurotransmitter — when GABA is already present. The result is enhanced inhibitory signaling throughout the central nervous system, producing sedation, anxiolysis, muscle relaxation, and anticonvulsant activity.
No substance-specific binding data have been published for metizolam. Its mechanism is inferred from the thienotriazolodiazepine structure and confirmed indirectly by the observation that flumazenil — a GABA-A antagonist — reversed CNS depression in documented NPS benzodiazepine intoxications.[7] A quantitative structure-activity model predicted higher binding affinity for triazolobenzodiazepines than for classical benzodiazepines, though no specific estimate for metizolam was extractable.[10][4]
Pharmacokinetics
Human pharmacokinetic data for metizolam are extremely limited. The only published data come from a single controlled study in one adult male volunteer who ingested a 2 mg oral dose.[6]
Absorption characteristics — peak plasma time, bioavailability, and distribution — have not been measured. By analogy to etizolam, which reaches peak concentrations within 0.5–2 hours,[11] metizolam is expected to absorb rapidly after oral administration.inferred
The compound undergoes extensive liver metabolism. Three hydroxylated metabolites were identified, with the primary metabolite (hydroxylation of the ethyl group) detectable in urine at 8 and 30 hours post-dose.[6] Only about 0.3% of the dose appeared as unchanged metizolam in urine, confirming near-complete hepatic processing.[6] The urinary detection window was 46 hours.
No plasma half-life has been measured. For reference, Etizolam has a half-life of approximately 3.4 hours, with its active metabolite extending to about 8.2 hours.[11] Standard benzodiazepine immunoassay screens may not detect metizolam; confirmatory mass spectrometry is required for reliable identification.[3][4]
Neuroscience[edit]
Where it acts
Metizolam enhances inhibitory GABA signaling across multiple brain regions. In the cortex, this suppression reduces excitability and produces sedation and amnesia — effects mediated primarily through receptors containing the alpha-1 subunit.[12] In the amygdala, enhanced GABA tone dampens fear responses and anxiety through alpha-2 and alpha-3 subunit-containing receptors.[12] Spinal cord inhibition produces muscle relaxation, while brainstem depression at high doses or in combination with other depressants can suppress breathing.
Tolerance and neuroadaptation
Repeated benzodiazepine exposure triggers compensatory changes in the brain: GABA-A receptors are downregulated, their subunit composition shifts, and the opposing excitatory glutamate system ramps up.[12] These adaptations produce tolerance, physical dependence, and the withdrawal. Tolerance to sedation and seizure protection develops faster than tolerance to anxiety suppression — a dissociation that explains why long-term users may still experience anxiolysis while requiring escalating doses for sleep.
No neuroimaging or electrophysiology studies have been conducted with metizolam. Key unknowns include whether the desmethyl modification alters subtype selectivity relative to etizolam (potentially changing the balance of sedation versus anxiolysis), whether the primary metabolite is pharmacologically active (as alpha-hydroxyetizolam is for etizolam), and whether metizolam's predicted binding affinity from structural models reflects its actual potency in the living brain.
Subjective Effects[edit]
Metizolam produces the characteristic benzodiazepine experience: a progressive softening of anxiety, cognitive edge, and muscle tension. The compound's low potency among designer benzodiazepines means the transition from threshold to strong effects spans a wider milligram range than with high-potency analogs, but the qualitative character remains class-typical. Set, prior benzodiazepine tolerance, and concurrent substance use substantially alter depth and duration. The amnestic component is dose-dependent and frequently underestimated during the experience itself.
Relative to etizolam, metizolam is reported as less potent and less euphoric.[1] The overall experiential profile is closer to pyrazolam or deschloroetizolam — functional anxiety suppression with moderate sedation — than to the heavily sedating designer benzodiazepines like flubromazolam or clonazolam.
Effect Grid
Clear anxiolysis dominates the experience, accompanied by moderate sedation and evident muscle relaxation. The characteristic benzodiazepine state is fully established — a dampening of cognitive sharpness, emotional reactivity, and physical tension.
Analysis suppression and thought deceleration are clearly present. Mild amnesia becomes possible, particularly for events occurring during the peak. Emotional suppression begins to flatten affect noticeably. Motor control impairment is evident in fine motor tasks and gait.
Disinhibition emerges at this tier, and delusions of sobriety may lead users to underestimate their level of impairment. Physical fatigue and drowsiness increase, particularly in the offset phase.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing suppression
Body high · Dizziness · Dry mouth · Nystagmus (eye wobbles) · Nausea
Nausea
Information processing suppression · Memory suppression · Analysis suppression · Cognitive euphoria · Thought deceleration · Language suppression · Memory fragmentation · Motivation suppression · Suggestibility enhancement · Compulsive redosing urge · Confusion · Thought disorganization · Humor enhancement · Amnesia · Delirium
Cognitive euphoria · Thought deceleration · Language suppression · Memory fragmentation · Motivation suppression · Compulsive redosing urge · Confusion · Thought disorganization · Humor enhancement · Amnesia · Delirium
Craving · Sociability suppression · Depersonalization · Derealization
Timeline
Gradual emergence of mild anxiolysis and subtle muscular relaxation. Effects may be difficult to distinguish from placebo at lower doses. The wide onset window (30–90 minutes) tempts premature redosing.
Deepening sedation and muscle relaxation become clearly perceptible. Anxiety suppression strengthens. Mild cognitive slowing begins.
Full anxiolysis, moderate-to-strong sedation, and cognitive suppression. Amnesia becomes possible at common doses and likely at strong doses. Disinhibition and emotional blunting are most pronounced.
Gradual return of baseline anxiety and cognitive function. Residual sedation and muscle relaxation persist. Motor coordination slowly recovers.
Residual drowsiness, mild cognitive fog, and possible rebound anxiety. Dreaming enhancement may occur during subsequent sleep.
⚠ Avoid driving or operating heavy machinery for at least 12 hours after use due to residual sedation and cognitive impairment.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Severefatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- High
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- benzodiazepines · thienodiazepines · zolpidem
Toxicity
No formal toxicity studies have been conducted for metizolam in any species.safety citation needed Benzodiazepines and thienodiazepines as a class carry a large therapeutic index when used alone — death from oral benzodiazepine overdose without co-ingestants is rare.[5][4] No metizolam-specific fatalities have been reported in the published literature.
Four confirmed metizolam intoxication cases appeared in the Swedish STRIDA project between 2012 and 2016.[7] Across the broader STRIDA dataset of 217 NPS benzodiazepine cases, CNS depression was the primary clinical sign, 89% involved concurrent polysubstance use, and all patients exposed to NPS benzodiazepines alone responded to flumazenil.[7]
Polysubstance lethality
The primary lethal risk is combined use with other CNS depressants. Opioid-benzodiazepine combinations produce synergistic respiratory depression — GABA-A enhancement and opioid receptor activation suppress breathing through complementary mechanisms.[3] Alcohol, barbiturates, gabapentinoids, GHB, and z-drugs each add to this respiratory and CNS depression.
Immunoassay detection gap
Standard hospital benzodiazepine drug screens may not detect metizolam, creating a risk of undiagnosed intoxication in emergency settings.[3][4] Confirmatory mass spectrometry is required for reliable identification.[6]
Product adulteration
Preparations from unregulated sources may be adulterated with opioids or other substances, mislabeled in dose or identity, or contain degradation products.[8][3] This elevates risk substantially beyond the pharmacological profile of the pure compound.
Psychological Risks
No controlled studies of metizolam's psychological effects exist. Class-level risks include:
- Amnesia — Anterograde amnesia is a core pharmacological effect, worsening with dose. Users may have no memory of actions taken while intoxicated, which becomes especially dangerous alongside disinhibition.
- Disinhibition — Benzodiazepines can produce paradoxical disinhibition, aggression, or risk-taking, particularly at higher doses or with alcohol.
- Delusions of sobriety — Users frequently underestimate their impairment, leading to dangerous decisions including driving, redosing, or adding other substances.
- Compulsive redosing — The combination of anxiolysis, amnesia, and impaired judgment creates a pattern where users redose without remembering prior doses.[8]
Designer benzodiazepines including metizolam have been identified as agents of drug-facilitated sexual assault due to their amnestic and sedative properties.[13]
Tolerance & Dependence
Benzodiazepine tolerance develops through GABA-A receptor downregulation and subunit composition changes.[12] Tolerance to sedation and seizure protection develops faster than tolerance to anxiety relief. Community reports suggest metizolam tolerance builds within days of repeated use, with full reset in approximately 1.5 weeks.safety citation needed
Cross-tolerance exists with all benzodiazepine-site ligands — classical benzodiazepines, other thienodiazepines, and z-drugs (zolpidem, zopiclone, zaleplon).
Physical dependence can develop within weeks of daily use. Etizolam — metizolam's closest structural analog — has documented dependence cases[14] despite initial marketing claims of lower liability. No metizolam-specific dependence data exist, but the class-level risk is substantial.
Benzodiazepine withdrawal includes rebound effect anxiety, insomnia, tremor, and autonomic instability. Abrupt cessation after dependence carries seizure risk that may be life-threatening.safety citation needed Gradual tapering under medical supervision is the standard approach to discontinuation.
Drug Interactions
All interaction data are inferred from benzodiazepine class pharmacology. No metizolam-specific interaction studies exist.
Opioids produce synergistic respiratory depression through complementary receptor mechanisms.[3] Alcohol potentiates both CNS and respiratory depression. Barbiturates, GHB/GBL, gabapentinoids (pregabalin, gabapentin), and z-drugs each carry additive or synergistic depressant risk.
Drugs that inhibit the liver enzyme CYP3A4 — including azole antifungals, macrolide antibiotics, and HIV protease inhibitors — may increase metizolam blood levels by slowing its breakdown, as demonstrated with itraconazole and Etizolam.[15]inferred CYP inducers such as carbamazepine may accelerate metizolam metabolism and reduce its effects.[16]inferred
Contraindications
No metizolam-specific contraindication data exist. The following are inferred from benzodiazepine class pharmacology:
- Concurrent opioid use — Synergistic respiratory depression carries mortality risk.
- Concurrent alcohol intoxication — Additive CNS and respiratory depression.
- Respiratory insufficiency — Benzodiazepine-induced respiratory depression may precipitate respiratory failure.
- Severe liver impairment — Metizolam undergoes liver metabolism; impaired clearance may prolong and intensify effects.inferred
- Pregnancy — Benzodiazepines cross the placenta and are associated with neonatal withdrawal syndrome.safety citation needed
- Myasthenia gravis — muscle relaxation may worsen neuromuscular weakness.
- History of substance use disorder — Elevated risk of dependence and compulsive use.
Flumazenil considerations: Flumazenil reversed CNS depression in documented NPS benzodiazepine intoxications.[7] However, flumazenil itself carries risks — a meta-analysis found significantly increased adverse events versus placebo, including heart rhythm disturbances and convulsions.[17] Administration requires clinical judgment and is not a routine intervention.
Harm Reduction[edit]
Forms & Identification
Metizolam circulates exclusively through unregulated research chemical vendors. Reagent test kits cannot reliably distinguish between different benzodiazepine analogs — a positive result confirms the presence of a benzodiazepine-class compound but cannot verify which one. Drug-checking services offering FTIR or mass spectrometry provide the only reliable identity confirmation.
Given the documented risk of mislabeling and adulteration in designer benzodiazepine markets,[8] using fentanyl test strips and confirming chemical identity through analytical services are both advisable before use.
Guidelines
- Start with the lowest available dose and wait at least 2 hours before considering redosing — onset and peak may be slower than expected.
- Use a milligram-precision scale for powder forms. Do not estimate doses by eye.
- Write down the time and amount of each dose before taking it. Amnesia makes mental tracking unreliable.
- Do not combine with opioids, alcohol, or other depressants under any circumstances.
- Do not drive or operate machinery.
- Inform a trusted person of what you are taking and when.
- Set a hard limit on the total amount available for the session — remove excess supply from reach before dosing.
- Avoid daily or consecutive-day use. Physical dependence can develop within weeks.
Set & Setting
Benzodiazepines impair judgment, coordination, and memory formation. Use in an unfamiliar or unsafe environment increases the risk of injury, dangerous decisions, and victimization. A trusted, sober companion reduces these risks significantly.
Avoid situations requiring motor coordination, driving, or consequential decision-making. The amnestic effects mean users may not recall events during the experience — a safe, private environment is especially important.
Aftercare & integration. Benzodiazepine aftereffects are typically mild compared to stimulant or psychedelic recovery. Residual sedation and cognitive dulling may persist for 12–24 hours after use. Allow adequate sleep and avoid demanding cognitive tasks the following day.
Review any notes or messages sent during the experience — amnesia may have obscured consequential actions or communications. If use was motivated by anxiety or insomnia, consider addressing the underlying condition through professional support rather than repeated self-medication.
Recovery & Support
Benzodiazepine dependence develops insidiously — what begins as occasional use for anxiety or sleep can become daily reliance within weeks. If metizolam use has become regular, do not stop abruptly — benzodiazepine withdrawal can produce life-threatening seizures. A gradual taper under medical supervision is the standard and safest approach to discontinuation.
Support resources include physicians experienced in benzodiazepine tapering, addiction medicine specialists, and peer support organizations. The Benzodiazepine Information Coalition (benzoinfo.com) and online communities such as BenzoBuddies provide peer guidance and tapering protocols. For immediate crisis support, SAMHSA's National Helpline (1-800-662-4357) offers free, confidential referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing becomes slow, shallow, or stops
- Lips or fingertips turn blue
- Person is unresponsive to shouting or sternal rub
- Seizure activity
- Severe confusion or agitation beyond what the dose would explain
Immediate steps:
- 1. Call emergency services immediately if breathing is compromised or the person is unresponsive.
- 2. Place the person in the recovery position (on their side, airway clear).
- 3. Do not leave them alone.
- 4. Do not induce vomiting.
- 5. If opioid co-ingestion is suspected and naloxone is available, administer it — naloxone will not reverse benzodiazepine effects but will address the opioid component.
What to tell the dispatcher: Name the substance (metizolam or designer benzodiazepine), approximate dose and time taken, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution.
Reversal agent: Flumazenil can reverse benzodiazepine-induced CNS depression but carries its own risks including seizures — its use is a clinical decision, not a field intervention.
Legal Status[edit]
Metizolam is not scheduled under any international convention. The United Nations Convention on Psychotropic Substances does not list metizolam, and the WHO Expert Committee on Drug Dependence has not issued a scheduling recommendation. National scheduling varies — several European nations and Canada have explicitly controlled it, while it remains unscheduled at the federal level in the United States.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | Not included in the 2025 DEA scheduling action that permanently controlled clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam. The Federal Analogue Act may apply if intended for human consumption. State laws vary.citation needed |
| United Kingdom | Class C, Schedule 1 | Controlled since May 2017 under the Misuse of Drugs Act 1971 (Amendment) Order 2017. Possession, production, supply, import, and export prohibited without authorization.[18] |
| Sweden | Controlled substance | Classified as a controlled substance on January 26, 2016.[9] |
| Germany | Controlled (NpSG) | Controlled under the New Psychoactive Substances Act since July 18, 2019. Permitted for industrial and scientific use only.citation needed |
| Canada | Schedule IV (CDSA) | All benzodiazepines are Schedule IV controlled substances under the Controlled Drugs and Substances Act.citation needed |
| Denmark | Controlled | Placed under national control; specific date not confirmed.citation needed |
| Finland | Controlled | Placed under national control; specific date not confirmed.citation needed |
| Australia | Likely Schedule 9 (unconfirmed) | Scheduling status not confirmed from primary sources.citation needed |
references
- [1] ^abcEl Balkhi S, Monchaud C, Herault F, Geniaux H, Saint-Marcoux F (2020) Designer benzodiazepines' pharmacological effects and potencies: How to find the information — Journal of Psychopharmacology doi:10.1177/0269881119901096
- [2]
- [3]
- [4]
- [5] ^abcBrunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP (2021) Designer Benzodiazepines: A Review of Toxicology and Public Health Risks — Pharmaceuticals doi:10.3390/ph14060560
- [6]